TABLE 2

Comparison of Growth and Neurodevelopmental Outcomes

Bevacizumab (n = 27)Laser (n = 98)Unadjusted OR (95% CI)Adjusted ORa (95% CI)
Weight, mean (SD), kg9.9 (1.4)10.2 (1.5)
Length, mean (SD), cm79.7 (4.1)79.5 (3.4)
Head circumference, mean (SD), cm46.5 (1.6)46.3 (1.9)
Cerebral palsy, n (%)<5b11 (12)
Hearing aids, n (%)<5b6 (6)
Any visual problem, n (%)13 (48)42 (44)
Bilateral blindness, n (%)<5b5 (5)
Bayley-3 scores, median (IQR)
 Cognition90 (80–100)90 (85–100)
 Language composite79 (65–97)89 (74–97)
 Motor composite81 (70–91)88 (79–97)*
Bayley-3 scores <85, n (%)
 Cognition11/26 (42)22/89 (25)2.2 (0.9–5.6)2.6 (0.9–7.7)
 Language composite15/25 (60)35/85 (41)2.1(0.9–5.3)2.0 (0.7–5.3)
 Motor composite13/25 (52)26/86 (30)2.5 (1.0–6.2)*2.3 (0.8–6.1)
Neurodevelopmental impairment, n (%)21 (78)55 (56)2.7 (1.0–7.4)*3.0 (0.97–9.0)
Severe neurodevelopmental disability, n (%)14 (52)28 (29)2.7 (1.1–6.4)*3.1 (1.2–8.4)*
  • CI, confidence interval; IQR, interquartile range; OR, odds ratio.

  • a Adjusted for GA, male gender, maternal education, SNAP-II score, bronchopulmonary dysplasia, sepsis, and grade 3 or 4 intraventricular hemorrhage.

  • b According to network policy, any cell with values <5 is suppressed to avoid possibility of reidentification.

  • * P < .05.